• Home
  • About
    • Who We Are
    • Mission
    • Values
  • Science & Pipeline
  • Patients
  • Leadership
  • Investors & Media
    • Overview
    • Press Releases
    • Events
    • Publications / Presentations
    • Financial Information
    • Corporate Governance
    • Stock Information
    • Investor Resources
  • Careers
  • Contact Us
  • LinkedIn
  • Privacy
  • Terms of Use

Kinnate Biopharma Closes $74.5M Series B Financing

by Kinnate Biopharma | Dec 19, 2019 | News

Kinnate Biopharma Closes $74.5M Series B Financing New investors OrbiMed, Nextech Invest and Vida Ventures join existing investors Foresite Capital and Eshelman Ventures. Proceeds will be used to advance multiple precision oncology drug candidates into the clinic. SAN...

Recent Posts

  • Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the Board
  • Kinnate Biopharma Closes $98 Million Series C Financing
  • Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical Officer
  • Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year
  • Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer

Recent Comments

    Archives

    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • December 2019
    • April 2018

    Categories

    • Article
    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    LinkedIn
    Expanded Access
    Contact
    Privacy
    Terms of Use
    © 2024 Kinnate Biopharma.

    On April 3, 2024, XOMA completed its acquisition of Kinnate. Visit XOMA.com